This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Atreca han disminuido a una tasa media anual de -14.6%, mientras que en la industria Biotechs los beneficios crecieron en un 19.3% anualmente.

Información clave

-14.6%

Tasa de crecimiento de los beneficios

51.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera	-908.6%
Margen neto	n/a
Última actualización de beneficios	30 Sep 2023

Actualizaciones de resultados anteriores recientes

No hay actualizaciones

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero Atreca. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

OTCPK:BCEL Ingresos, gastos y beneficios (USD Millions)
Fecha	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 23	-98	36	45
30 Jun 23	-85	38	51
31 Mar 23	-93	39	58
31 Dec 22	-97	39	62
30 Sep 22	-105	40	68
30 Jun 22	-110	41	70
31 Mar 22	-108	43	67
31 Dec 21	-109	43	67
30 Sep 21	-103	42	61
30 Jun 21	-98	42	59
31 Mar 21	-92	38	55
31 Dec 20	-86	37	52
30 Sep 20	-83	37	50
30 Jun 20	-76	33	48
31 Mar 20	-74	29	50
31 Dec 19	-67	24	49
30 Sep 19	-59	17	48
30 Jun 19	-53	13	43
31 Mar 19	-44	11	35
31 Dec 18	-38	9	31

Ingresos de calidad: BCEL actualmente no es rentable.

Margen de beneficios creciente: BCEL actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: BCEL no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 14.6% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de BCEL en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: BCEL no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (16.6%).

Rentabilidad financiera

Alta ROE: BCEL tiene una rentabilidad financiera negativa (-908.6%), ya que actualmente no es rentable.

This company listing is no longer active

Atreca Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Recent updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

New major risk - Financial position

Atreca, Inc. Announces Board Resignations

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca Receives Notice from the Nasdaq Stock Market

Atreca, Inc. Reduces its Workforce by Approximately 40%

New major risk - Revenue and earnings growth

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract

Insufficient new directors

Price target decreased by 24% to US$9.44

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Price target increased to US$15.57

Atreca GAAP EPS of -$0.72 misses by $0.02

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Index

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Price target decreased to US$16.63

Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101

Atreca: Biotech With Promise Based On First Candidate ATRC-101

Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology

Founder notifies of intention to sell stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$19.56

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

Founder notifies of intention to sell stock

Atreca: Safety Data Brought Down Stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$25.33

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth Index

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Chief Scientific Officer has left the company

Atreca, Inc Announces Executive Changes

Chief Business Officer has left the company

New 90-day low: US$13.00

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

Co-Founder notifies of intention to sell stock

New 90-day high: US$15.82

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Atreca EPS misses by $0.06

Director notifies of intention to sell stock

New 90-day high: US$15.79

New 90-day low - US$12.67

Analysts update estimates

New 90-day low - US$14.63

Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado